We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non-Invasive Liquid-Based Cytology Test Enables Early Endometrial Cancer Detection

By LabMedica International staff writers
Posted on 01 Aug 2025

Endometrial cancer is the fourth most common cancer among women in the United States, with over 69,000 new cases expected in 2025. More...

Yet many diagnoses occur late, particularly in women who face inconclusive imaging results, discomfort with invasive biopsy procedures, or limited access to specialized care. Nearly 30 percent of biopsies result in insufficient tissue, often requiring repeat procedures that delay timely diagnosis. This diagnostic gap is even more pronounced in women with abnormal uterine bleeding, chronic anovulation, postmenopausal symptoms, elevated body mass index (BMI), a history of endometrial hyperplasia, or increased cancer risk due to Tamoxifen therapy or Lynch syndrome. With over 34 million women in the U.S. living with elevated BMI, 6 million diagnosed with PCOS, and millions more globally facing hereditary risks, the demand for improved diagnostic options is critical. Now, a non-invasive solution aims to support earlier and more accessible endometrial cancer detection for high-risk women.

Gnosis (Orange, CA, USA) has developed EdenDx (Early Detection for Endometrial Neoplasia), a non-invasive liquid-based cytology test for early-stage endometrial cancer detection. Powered by the proprietary epiHERA technology from INEX Innovate (Singapore), EdenDx collects endocervical samples using a cervical brush or broom during routine pelvic exams and preserves them in a ThinPrep vial. The test analyzes the hypermethylation of two genes, CDO1 and CELF4, which are strongly linked to endometrial cancer. Designed to integrate seamlessly into existing clinical workflows, EdenDx delivers results within 3 to 7 days, helping healthcare providers assess risk and make timely, informed decisions. The test aims to fill a critical diagnostic gap in gynecologic care by offering an accessible and patient-friendly method that complements traditional biopsy procedures without introducing complexity.

In validation studies, EdenDx demonstrated a specificity of 97.8% and a sensitivity of 85.3%, including in cases of high-grade cancers. While not intended to replace biopsy, EdenDx can reduce the number of unnecessary biopsies and improve care efficiency. It is now available for use during routine well-woman and pelvic exams. The test is designed to serve women who have historically been underserved by conventional diagnostic tools, offering a scalable, real-world solution that aligns with the mission of expanding access to early detection technologies. Gnosis is actively partnering with providers to make EdenDx widely available and impactful across diverse healthcare settings.

“EdenDx represents one of the most meaningful advances in gynecologic diagnostics in years. It gives providers earlier, clearer insight using a process that is familiar and comfortable for patients,” said Dr. Safedin Beqaj, Clinical Laboratory Director at Gnosis. “This is what diagnostic innovation should look like—real-world, patient-centered, and ready to use."

Related Links:
Gnosis 
INEX Innovate


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.